SURGE Therapeutics.

An operating room, the moment after the tumor leaves

The surgeon has done the hard part. The mass is in a specimen tray, the margins look clean, and everyone in the room exhales. SURGE Therapeutics is interested in the next ninety seconds - the ones nobody usually thinks about. Because that open cavity, full of inflammation and stray cells, is where cancer quietly plans its return. SURGE wants to put a drug there before the surgeon closes.

The company is small - a Cambridge team you could fit around one large table - and its idea is almost rude in its simplicity. Surgery removes the tumor you can see. SURGE goes after the disease you can't. Its tool is a biodegradable hydrogel called SURGERx, placed directly into the wound, engineered to release immunotherapy where recurrence actually begins and then to disappear when its work is done.

Surgery saves lives. Then it hands cancer an opening.

Here is the uncomfortable part of a successful operation. Cutting a tumor out triggers exactly the kind of inflammation a body needs to heal a wound - and exactly the kind that can switch the local immune environment from watchdog to bystander. Residual cells, invisible on any scan, take advantage. The result shows up years later as a number that doesn't get said out loud often enough.

Systemic immunotherapy works, but it floods the whole body to reach a few square centimeters that matter most. SURGE's bet is geographic: concentrate the dose where the danger lives, and spare everywhere it doesn't. It is a deceptively old idea - location, location, location - applied to a field that usually thinks in bloodstreams.

From a Harvard lab to a category that didn't exist

Michael Goldberg, Ph.D., did not set out to start a company so much as to finish an argument. A biomedical engineer working in localized immunotherapy at Harvard Medical School, he kept returning to the same inconvenient question: if the riskiest moment for recurrence is the surgery itself, why does immunotherapy almost always arrive weeks later and everywhere at once? SURGE Therapeutics is his answer, and the answer required inventing a label - "The Intraoperative Immunotherapy Company" - because there wasn't one to borrow.

Naming your own category is either confidence or a tell. Investors apparently read it as the former. Camford Capital led a $26M Series A in 2022; Bioluminescence Ventures led a $32M Series B in 2023. Khosla Ventures, 8VC, and the Cancer Research Institute came along for both. That is roughly $58M wagered on a gel and a sense of timing.

A gel that does its job, then politely dissolves

SURGERx is the platform; SRG-514 is the lead candidate built on it. Together they turn a surgical cavity into a slow-release immunotherapy depot - high local exposure, low everywhere else, no implant left behind. The pipeline reaches past one disease, which is the whole point of building a platform rather than a single product.

The case so far, in numbers

Belief is cheap in biotech; capital and clinical data are not. SURGE has accumulated both. The funding tells you who's convinced. The clinic tells you whether they should be.

Funding figures are company-reported via Business Wire and FinSMES (Series A: $26M, Oct 2022; Series B: $32M, Jul 2023). Total funding ~$58M. Investor lists compiled from public financing announcements and may vary slightly by source.

Make the operating room an immunotherapy clinic

Strip away the hydrogel chemistry and the trademark, and SURGE is arguing for a change in timing. Adjuvant therapy says: remove the tumor, recover, then fight what's left. SURGE says: fight what's left while you're still in there. It's a small shift in sequence with a large shift in logic - treat the disease at the place and the moment it's most vulnerable, not the most convenient.

If it works, the win isn't a flashy new molecule. It's a quieter outcome: fewer people sitting in a follow-up appointment years later, hearing the word "recurrence." That is a harder thing to market and a better thing to build.

Back in that operating room

Return to the cavity, the exhale, the ninety seconds. In SURGE's version of that room, the surgeon doesn't just close. A dose of SURGERx goes in first - a gel that turns the wound's own inflammation against the cells trying to use it, then dissolves and leaves nothing to explain on a future scan. The operation that removed the tumor becomes the same operation that goes after what it left behind.

That future isn't proven yet. SRG-514 has cleared Phase 1 and a registrational trial is the next, much larger test. Plenty of elegant biotech ideas have died exactly here. But the premise is unusually clean: the riskiest moment is also the best moment to act, and almost no one is acting in it. SURGE Therapeutics is betting the whole company on that one open window - and on closing it for good.